Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Abdominal Radiology
Published in: Abdominal Radiology 6/2009

01-11-2009

Functional MR imaging as a new paradigm for image guidance

Authors: Lia Assumpcao, Michael Choti, Timothy M. Pawlik, Jean-Francois Gecshwind, Ihab R. Kamel

Published in: Abdominal Radiology | Issue 6/2009

Login to get access

Abstract

Guidance and monitoring of locoregional minimally invasive treatment for primary or secondary liver tumor are critical to ensuring success and efficacy of therapy. In this article, we review advanced MR imaging techniques, including MR spectroscopy, diffusion and perfusion MR imaging, which can provide essential in vivo physiologic and metabolic information. These innovative imaging techniques can provide potential additional criteria to assess tumor response in addition to the accepted yet often limited Response Evaluation Criteria in Solid Tumors (RECIST) and the European Association for the Study of the Liver (EASL) criteria, which are based on decrease of tumor size and lesion enhancement, respectively. In this article, we also discuss the role of tumor size and enhancement in addition to apparent diffusion coefficient (ADC) findings after radiofrequency ablation (RFA), transarterial chemoembolization (TACE), and radioembolization.
Literature
1.
Law M, Hamburger M, Johnson G, et al. (2004) Differentiating surgical from non-surgical lesions using perfusion MR imaging and proton MR spectroscopic imaging. Technol Cancer Res Treat 3:557–565PubMed
2.
Kos S, Huegli R, Bongartz GM, Jacob AL, Bilecen D (2008) MR-guided endovascular interventions: a comprehensive review on techniques and applications. Eur Radiol 18:645–657CrossRefPubMed
3.
Rhee TK, Larson AC, Prasad PV, et al. (2005) Feasibility of blood oxygenation level-dependent MR imaging to monitor hepatic transcatheter arterial embolization in rabbits. J Vasc Interv Radiol 16:1523–1528PubMed
4.
Vossen JA, Buijs M, Kamel IR (2006) Assessment of tumor response on MR imaging after locoregional therapy. Tech Vasc Interv Radiol 9:125–132CrossRefPubMed
5.
Dodd GD 3rd, Soulen MC, Kane RA, et al. (2000) Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough. Radiographics 20:9–27PubMed
6.
Goldberg SN, Ahmed M (2002) Minimally invasive image-guided therapies for hepatocellular carcinoma. J Clin Gastroenterol 35:S115–S129CrossRefPubMed
7.
Bartolozzi C, Lencioni R, Caramella D, et al. (1994) Hepatocellular carcinoma: CT and MR features after transcatheter arterial embolization and percutaneous ethanol injection. Radiology 191:123–128PubMed
8.
Lencioni R, Caramella D, Bartolozzi C (1995) Hepatocellular carcinoma: use of color Doppler US to evaluate response to treatment with percutaneous ethanol injection. Radiology 194:113–118PubMed
9.
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214CrossRefPubMed
10.
Therasse P, Arbuck SG, Eisenhauer EA, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMed
11.
Kamel IR, Bluemke DA (2002) Magnetic resonance imaging of the liver: assessing response to treatment. Top Magn Reson Imaging 13:191–200CrossRefPubMed
12.
Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430CrossRefPubMed
13.
Padhani AR, Leach MO (2005) Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom Imaging 30:324–341CrossRefPubMed
14.
Goh V, Padhani AR (2006) Imaging tumor angiogenesis: functional assessment using MDCT or MRI? Abdom Imaging 31:194–199CrossRefPubMed
15.
Kim YK, Kwak HS, Kim CS, et al. (2006) Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIO-enhanced MR imaging and 16-detector row CT. Radiology 238:531–541CrossRefPubMed
16.
Lankester KJ, Taylor JN, Stirling JJ, et al. (2007) Dynamic MRI for imaging tumor microvasculature: comparison of susceptibility and relaxivity techniques in pelvic tumors. J Magn Reson Imaging 25:796–805CrossRefPubMed
17.
Miyazaki K, Collins DJ, Walker-Samuel S, et al. (2008) Quantitative mapping of hepatic perfusion index using MR imaging: a potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor. Eur Radiol 18:1414–1421CrossRefPubMed
18.
Leach MO, Brindle KM, Evelhoch JL, et al. (2005) The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Brit J Cancer 92:1599–1610CrossRefPubMed
19.
Leveson SH, Wiggins PA, Giles GR, Parkin A, Robinson PJ (1985) Deranged liver blood flow patterns in the detection of liver metastases. Brit J Surg 72:128–130CrossRefPubMed
20.
Law M, Yang S, Wang H, et al. (2003) Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Ajnr 24:1989–1998PubMed
21.
Yeung DK, Cheung HS, Tse GM (2001) Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy–initial results. Radiology 220:40–46PubMed
22.
Jagannathan NR, Kumar M, Seenu V, et al. (2001) Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Brit J Cancer 84:1016–1022CrossRefPubMed
23.
Wu B, Peng WJ, Wang PJ, et al. (2006) In vivo 1H magnetic resonance spectroscopy in evaluation of hepatocellular carcinoma and its early response to transcatheter arterial chemoembolization. Chinese Med Sci J = Chung-kuo i hsueh k’o hsueh tsa chih/Chinese Acad Med Sci 21:258–264
24.
Bertram HC, Duarte IF, Gil AM, Knudsen KE, Laerke HN (2007) Metabolic profiling of liver from hypercholesterolemic pigs fed rye or wheat fiber and from normal pigs. High-resolution magic angle spinning 1H NMR spectroscopic study. Anal Chem 79:168–175CrossRefPubMed
25.
Duarte IF, Stanley EG, Holmes E, et al. (2005) Metabolic assessment of human liver transplants from biopsy samples at the donor and recipient stages using high-resolution magic angle spinning 1H NMR spectroscopy. Anal Chem 77:5570–5578CrossRefPubMed
26.
Longo R, Ricci C, Masutti F, et al. (1993) Fatty infiltration of the liver. Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography. Invest Radiol 28:297–302CrossRefPubMed
27.
Xu H, Li X, Yang ZH, Xie JX (2006) In vivo 1H MR spectroscopy in the evaluation of the serial development of hepatocarcinogenesis in an experimental rat model. Acad Radiol 13:1532–1537CrossRefPubMed
28.
Hara T, Bansal A, DeGrado TR (2006) Choline transporter as a novel target for molecular imaging of cancer. Mol Imaging 5:498–509PubMed
29.
Taouli B, Vilgrain V, Dumont E, et al. (2003) Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology 226:71–78CrossRefPubMed
30.
Moffat BA, Chenevert TL, Lawrence TS, et al. (2005) Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 102:5524–5529CrossRefPubMed
31.
Moffat BA, Chenevert TL, Meyer CR, et al. (2006) The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia (New York, NY) 8:259–267
32.
Ni H, Kavcic V, Zhu T, Ekholm S, Zhong J (2006) Effects of number of diffusion gradient directions on derived diffusion tensor imaging indices in human brain. Ajnr 27:1776–1781PubMed
33.
Moseley ME, Cohen Y, Kucharczyk J, et al. (1990) Diffusion-weighted MR imaging of anisotropic water diffusion in cat central nervous system. Radiology 176:439–445PubMed
34.
Yamada I, Aung W, Himeno Y, Nakagawa T, Shibuya H (1999) Diffusion coefficients in abdominal organs and hepatic lesions: evaluation with intravoxel incoherent motion echo-planar MR imaging. Radiology 210:617–623PubMed
35.
Graham SJ, Stanisz GJ, Kecojevic A, Bronskill MJ, Henkelman RM (1999) Analysis of changes in MR properties of tissues after heat treatment. Magn Reson Med 42:1061–1071CrossRefPubMed
36.
Kuehl H, Antoch G, Stergar H, et al. (2008) Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: initial results. Eur J Radiol 67:362–371CrossRefPubMed
37.
38.
Mahnken AH, Buecker A, Spuentrup E, et al. (2004) MR-guided radiofrequency ablation of hepatic malignancies at 1.5 T: initial results. J Magn Reson Imaging 19:342–348CrossRefPubMed
39.
Bartolozzi C, Crocetti L, Cioni D, Donati FM, Lencioni R (2001) Assessment of therapeutic effect of liver tumor ablation procedures0. Hepato-gastroenterol 48:352–358
40.
Rossi S, Buscarini E, Garbagnati F, et al. (1998) Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. Ajr 170:1015–1022PubMed
41.
Shibata T, Iimuro Y, Yamamoto Y, et al. (2002) Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology 223:331–337CrossRefPubMed
42.
Chopra S, Dodd GD 3rd, Chintapalli KN, et al. (2001) Tumor recurrence after radiofrequency thermal ablation of hepatic tumors: spectrum of findings on dual-phase contrast-enhanced CT. Ajr 177:381–387PubMed
43.
Sironi S, Livraghi T, Meloni F, et al. A (1999) Small hepatocellular carcinoma treated with percutaneous RF ablation: MR imaging follow-up. Ajr 173:1225–1229PubMed
44.
Curley SA, Izzo F, Delrio P, et al. (1999) Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg 230:1–8CrossRefPubMed
45.
Kamat PP, Gupta S, Ensor JE, et al. (2008) Hepatic arterial embolization and chemoembolization in the management of patients with large-volume liver metastases. Cardiovasc Interv Radiol 31:299–307CrossRef
46.
Wang D, Bangash AK, Rhee TK, et al. (2007) Liver tumors: monitoring embolization in rabbits with VX2 tumors–transcatheter intraarterial first-pass perfusion MR imaging. Radiology 245:130–139CrossRefPubMed
47.
Larson AC, Wang D, Atassi B, et al. (2008) Transcatheter intraarterial perfusion: MR monitoring of chemoembolization for hepatocellular carcinoma–feasibility of initial clinical translation. Radiology 246:964–971CrossRefPubMed
48.
Lou CY, Feng YM, Qian AR, et al. (2004) Establishment and characterization of human hepatocellular carcinoma cell line FHCC-98. World J Gastroenterol 10:1462–1465PubMed
49.
Kamel IR, Bluemke DA, Eng J, et al. (2006) The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol 17:505–512PubMed
50.
Kamel IR, Bluemke DA, Ramsey D, et al. (2003) Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. Ajr 181:708–710PubMed
51.
Pelletier G, Roche A, Ink O, et al. (1990) A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 11:181–184CrossRefPubMed
52.
Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. (1995) A comparison of lipiodol chemoembolization, conservative treatment for unresectable hepatocellular carcinoma. New Engl J Med 332:1256–1261
53.
Bruix J, Llovet JM, Castells A, et al. (1998) Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology (Baltimore, MD) 27:1578–1583CrossRef
54.
De Santis M, Alborino S, Tartoni PL, et al. (1997) Effects of lipiodol retention on MRI signal intensity from hepatocellular carcinoma and surrounding liver treated by chemoembolization. Eur Radiol 7:10–16CrossRefPubMed
55.
Ito K, Honjo K, Fujita T, et al. (1995) Therapeutic efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma: MRI and pathology. J Comput Assist Tomo 19:198–203CrossRef
56.
Kim T, Murakami T, Takahashi S, et al. (1999) Diffusion-weighted single-shot echoplanar MR imaging for liver disease. Ajr 173:393–398PubMed
57.
Khan SA, Miras A, Pelling M, Taylor-Robinson SD (2007) Cholangiocarcinoma and its management. Gut 56:1755–1756CrossRefPubMed
58.
Burger I, Hong K, Schulick R, et al. (2005) Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 16:353–361PubMed
59.
Gusani NJ, Balaa FK, Steel JL, et al. (2008) Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J Gastrointest Surg 12:129–137CrossRefPubMed
60.
Carty NJ, Foggitt A, Hamilton CR, Royle GT, Taylor I (1995) Patterns of clinical metastasis in breast cancer: an analysis of 100 patients. Eur J Surg Oncol 21:607–608CrossRefPubMed
61.
Li XP, Meng ZQ, Guo WJ, Li J (2005) Treatment for liver metastases from breast cancer: results and prognostic factors. World J Gastroenterol 11:3782–3787PubMed
62.
Buijs M, Kamel IR, Vossen JA, et al. (2007) Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging. J Vasc Interv Radiol 18:957–963CrossRefPubMed
63.
Touzios JG, Kiely JM, Pitt SC, et al. (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241:776–783; discussion 783–775CrossRefPubMed
64.
Norton JA (2005) Surgical treatment and prognosis of gastrinoma. Best Pract Res 19:799–805CrossRef
65.
Tomassetti P, Campana D, Piscitelli L, et al. (2005) Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol 16:1806–1810CrossRefPubMed
66.
Gupta S, Yao JC, Ahrar K, et al. (2003) Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J (Sudbury, Mass) 9:261–267CrossRef
67.
Roche A, Girish BV, de Baere T, et al. (2003) Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 13:136–140PubMed
68.
Eriksson BK, Larsson EG, Skogseid BM, et al. (1998) Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 83:2293–2301CrossRefPubMed
69.
Gupta S, Johnson MM, Murthy R, et al. (2005) Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104:1590–1602CrossRefPubMed
70.
Liapi E, Geschwind JF, Vossen JA, et al. (2008) Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. Ajr 190:67–73CrossRefPubMed
71.
Murthy R, Nunez R, Szklaruk J, et al. (2005) Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 25(Suppl 1):S41–S55CrossRefPubMed
72.
Geschwind JF, Salem R, Carr BI, et al. (2004) Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127:S194–S205CrossRefPubMed
73.
Andrews JC, Walker SC, Ackermann RJ, et al. (1994) Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 35:1637–1644PubMed
74.
Sarfaraz M, Kennedy AS, Cao ZJ, et al. (2003) Physical aspects of yttrium-90 microsphere therapy for nonresectable hepatic tumors. Med Phys 30:199–203CrossRefPubMed
75.
Buscombe JR, Padhy A (2001) Treatment of hepatocellular carcinoma: a pivotal role for nuclear medicine? Nucl Med Commun 22:119–120CrossRefPubMed
76.
Keppke AL, Salem R, Reddy D, et al. (2007) Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. Ajr 188:768–775CrossRefPubMed
77.
Miller FH, Keppke AL, Reddy D, et al. (2007) Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. Ajr 188:776–783CrossRefPubMed
78.
McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS (1990) Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108:1091–1096PubMed
79.
Kamel IR, Reyes DK, Liapi E, Bluemke DA, Geschwind JF (2007) Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 18:49–56CrossRefPubMed
80.
Deng J, Miller FH, Rhee TK, et al. (2006) Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization. J Vasc Interv Radiol 17:1195–1200PubMedCrossRef
81.
Sato KT, Lewandowski RJ, Mulcahy MF, et al. (2008) Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres–safety, efficacy, and survival. Radiology 247:507–515CrossRefPubMed
82.
Murthy R, Eng C, Krishnan S, et al. (2007) Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab. J Vasc Interv Radiol 18:1588–1591CrossRefPubMed
83.
Murthy R, Kamat P, Nunez R, et al. (2008) Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol 19:145–151CrossRefPubMed
Metadata
Title
Functional MR imaging as a new paradigm for image guidance
Authors
Lia Assumpcao
Michael Choti
Timothy M. Pawlik
Jean-Francois Gecshwind
Ihab R. Kamel
Publication date
01-11-2009
Publisher
Springer-Verlag
Published in
Abdominal Radiology / Issue 6/2009
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-008-9481-8

Other articles of this Issue 6/2009

Abdominal Radiology 6/2009 Go to the issue

OriginalPaper

Detection of anomalous splenic artery aneurysms with three-dimensional contrast-enhanced MR angiography

OriginalPaper

Target molecular therapies: methods to enhance and monitor tumor drug delivery

OriginalPaper

Pancreaticoduodenectomy: frequency and outcome of post-operative imaging-guided percutaneous drainage

OriginalPaper

Intestinal duplication in an adult patient diagnosed by multidetector computed tomography enteroclysis: report of a case

OriginalPaper

Pancreatic adenocarcinoma: dynamic 64-slice helical CT with perfusion imaging

OriginalPaper

An integrated MR/PET system: prospective applications
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits